

CLAIMS

1. Use of ganaxolone for the preparation of a medicament for the treatment of CDKL5 deficiency disorder in a human wherein the ganaxolone is to be administered by oral administration to a subject in an amount of 0.5 to 15 mg/kg/day; followed by progressively increasing the dose of ganaxolone over the course of 4 weeks to an amount from 18 mg/kg/day to 60 mg/kg/day, wherein the amount of ganaxolone administered does not exceed 1800 mg/day for a human that has a body weight greater than 30 kg.
2. The use of claim 1, wherein the ganaxolone is to be administered as an oral suspension.
3. The use of claim 1, wherein the ganaxolone is to be administered as an oral capsule.
4. The use of claim 1, wherein the ganaxolone is to be administered as a tablet.
5. The use of claim 2, wherein the ganaxolone is to be administered three times per day.
6. The use of claim 3 or claim 4, wherein the ganaxolone is to be administered two times per day.
7. The use of any one of claims 1 to 6, wherein the ganaxolone is to be administered to a subject that has a positive CDKL5 genetic mutation test result.